Major Companies for Small Interfering RNA (siRNA) Drugs Market: Alnylam, Novartis, Sylentis, Arrowhead, Silence Therapeutics, Dicerna.
Global Small Interfering RNA (siRNA) Drugs Market Size was estimated at USD 39970 million in 2022 and is projected to reach USD 52954.3747015571 million by 2028, exhibiting a CAGR of 4.8% during the forecast period.
Global Small Interfering RNA (siRNA) Drugs Market Overview And Scope:
The Global Small Interfering RNA (siRNA) Drugs Market Report 2024 provides comprehensive analysis of market development components, patterns, flows, and sizes. This research study of Small Interfering RNA (siRNA) Drugs utilized both primary and secondary data sources to calculate present and past market values to forecast potential market management for the forecast period between 2024 and 2032. It includes the study of a wide range of industry parameters, including government policies, market environments, competitive landscape, historical data, current market trends, technological innovations, upcoming technologies, and technological progress within related industries. Additionally, the report provides an in-depth analysis of the value chain and supply chain to demonstrate how value is added at every stage in the product lifecycle. The study incorporates market dynamics such as drivers, restraints/challenges, trends, and their impact on the market.
This Market Research Report provides a comprehensive analysis of the global Small Interfering RNA (siRNA) Drugs Market and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Small Interfering RNA (siRNA) Drugs portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Small Interfering RNA (siRNA) Drugs market.
Global Small Interfering RNA (siRNA) Drugs Market Segmentation
By Type, Small Interfering RNA (siRNA) Drugs market has been segmented into:
GIVLAARI
Onpattro
OXLUMO
AMVUTTRA
Leqvio
By Application, Small Interfering RNA (siRNA) Drugs market has been segmented into:
AHP
hATTR
Other
Regional Analysis of Small Interfering RNA (siRNA) Drugs Market:
North America (U.S., Canada, Mexico)
Eastern Europe (Bulgaria, The Czech Republic, Hungary, Poland, Romania, Rest of Eastern Europe)
Western Europe (Germany, UK, France, Netherlands, Italy, Russia, Spain, Rest of Western Europe)
Asia-Pacific (China, India, Japan, Singapore, Australia, New Zealand, Rest of APAC)
South America (Brazil, Argentina, Rest of SA)
Middle East & Africa (Turkey, Bahrain, Kuwait, Saudi Arabia, Qatar, UAE, Israel, South Africa)
Competitive Landscape of Small Interfering RNA (siRNA) Drugs Market:
Competitive analysis is the study of strength and weakness, market investment, market share, market sales volume, market trends of major players in the market.The Small Interfering RNA (siRNA) Drugs market study focused on including all the primary level, secondary level and tertiary level competitors in the report.The data generated by conducting the primary and secondary research. The report covers detail analysis of driver, constraints and scope for new players entering the Small Interfering RNA (siRNA) Drugs market.
Major Companies Covered in Small Interfering RNA (siRNA) Drugs market are:
Alnylam
Novartis
Sylentis
Arrowhead
Silence Therapeutics
Dicerna
Chapter 1: Introduction
1.1 Research Objectives
1.2 Research Methodology
1.3 Research Process
1.4 Scope and Coverage
1.4.1 Market Definition
1.4.2 Key Questions Answered
1.5 Market Segmentation
Chapter 2:Executive Summary
Chapter 3:Growth Opportunities By Segment
3.1 By Type
3.2 By Application
Chapter 4: Market Landscape
4.1 Porter's Five Forces Analysis
4.1.1 Bargaining Power of Supplier
4.1.2 Threat of New Entrants
4.1.3 Threat of Substitutes
4.1.4 Competitive Rivalry
4.1.5 Bargaining Power Among Buyers
4.2 Industry Value Chain Analysis
4.3 Market Dynamics
4.3.1 Drivers
4.3.2 Restraints
4.3.3 Opportunities
4.5.4 Challenges
4.4 Pestle Analysis
4.5 Technological Roadmap
4.6 Regulatory Landscape
4.7 SWOT Analysis
4.8 Price Trend Analysis
4.9 Patent Analysis
4.10 Analysis of the Impact of Covid-19
4.10.1 Impact on the Overall Market
4.10.2 Impact on the Supply Chain
4.10.3 Impact on the Key Manufacturers
4.10.4 Impact on the Pricing
Chapter 5: Small Interfering RNA (siRNA) Drugs Market by Type
5.1 Small Interfering RNA (siRNA) Drugs Market Overview Snapshot and Growth Engine
5.2 Small Interfering RNA (siRNA) Drugs Market Overview
5.3 GIVLAARI
5.3.1 Introduction and Market Overview
5.3.2 Historic and Forecasted Market Size (2017-2032F)
5.3.3 Key Market Trends, Growth Factors and Opportunities
5.3.4 GIVLAARI: Geographic Segmentation
5.4 Onpattro
5.4.1 Introduction and Market Overview
5.4.2 Historic and Forecasted Market Size (2017-2032F)
5.4.3 Key Market Trends, Growth Factors and Opportunities
5.4.4 Onpattro: Geographic Segmentation
5.5 OXLUMO
5.5.1 Introduction and Market Overview
5.5.2 Historic and Forecasted Market Size (2017-2032F)
5.5.3 Key Market Trends, Growth Factors and Opportunities
5.5.4 OXLUMO: Geographic Segmentation
5.6 AMVUTTRA
5.6.1 Introduction and Market Overview
5.6.2 Historic and Forecasted Market Size (2017-2032F)
5.6.3 Key Market Trends, Growth Factors and Opportunities
5.6.4 AMVUTTRA: Geographic Segmentation
5.7 Leqvio
5.7.1 Introduction and Market Overview
5.7.2 Historic and Forecasted Market Size (2017-2032F)
5.7.3 Key Market Trends, Growth Factors and Opportunities
5.7.4 Leqvio: Geographic Segmentation
Chapter 6: Small Interfering RNA (siRNA) Drugs Market by Application
6.1 Small Interfering RNA (siRNA) Drugs Market Overview Snapshot and Growth Engine
6.2 Small Interfering RNA (siRNA) Drugs Market Overview
6.3 AHP
6.3.1 Introduction and Market Overview
6.3.2 Historic and Forecasted Market Size (2017-2032F)
6.3.3 Key Market Trends, Growth Factors and Opportunities
6.3.4 AHP: Geographic Segmentation
6.4 hATTR
6.4.1 Introduction and Market Overview
6.4.2 Historic and Forecasted Market Size (2017-2032F)
6.4.3 Key Market Trends, Growth Factors and Opportunities
6.4.4 hATTR: Geographic Segmentation
6.5 Other
6.5.1 Introduction and Market Overview
6.5.2 Historic and Forecasted Market Size (2017-2032F)
6.5.3 Key Market Trends, Growth Factors and Opportunities
6.5.4 Other: Geographic Segmentation
Chapter 7: Company Profiles and Competitive Analysis
7.1 Competitive Landscape
7.1.1 Competitive Positioning
7.1.2 Small Interfering RNA (siRNA) Drugs Sales and Market Share By Players
7.1.3 Industry BCG Matrix
7.1.4 Heat Map Analysis
7.1.5 Small Interfering RNA (siRNA) Drugs Industry Concentration Ratio (CR5 and HHI)
7.1.6 Top 5 Small Interfering RNA (siRNA) Drugs Players Market Share
7.1.7 Mergers and Acquisitions
7.1.8 Business Strategies By Top Players
7.2 ALNYLAM
7.2.1 Company Overview
7.2.2 Key Executives
7.2.3 Company Snapshot
7.2.4 Operating Business Segments
7.2.5 Product Portfolio
7.2.6 Business Performance
7.2.7 Key Strategic Moves and Recent Developments
7.2.8 SWOT Analysis
7.3 NOVARTIS
7.4 SYLENTIS
7.5 ARROWHEAD
7.6 SILENCE THERAPEUTICS
7.7 DICERNA
Chapter 8: Global Small Interfering RNA (siRNA) Drugs Market Analysis, Insights and Forecast, 2017-2032
8.1 Market Overview
8.2 Historic and Forecasted Market Size By Type
8.2.1 GIVLAARI
8.2.2 Onpattro
8.2.3 OXLUMO
8.2.4 AMVUTTRA
8.2.5 Leqvio
8.3 Historic and Forecasted Market Size By Application
8.3.1 AHP
8.3.2 hATTR
8.3.3 Other
Chapter 9: North America Small Interfering RNA (siRNA) Drugs Market Analysis, Insights and Forecast, 2017-2032
9.1 Key Market Trends, Growth Factors and Opportunities
9.2 Impact of Covid-19
9.3 Key Players
9.4 Key Market Trends, Growth Factors and Opportunities
9.4 Historic and Forecasted Market Size By Type
9.4.1 GIVLAARI
9.4.2 Onpattro
9.4.3 OXLUMO
9.4.4 AMVUTTRA
9.4.5 Leqvio
9.5 Historic and Forecasted Market Size By Application
9.5.1 AHP
9.5.2 hATTR
9.5.3 Other
9.6 Historic and Forecast Market Size by Country
9.6.1 US
9.6.2 Canada
9.6.3 Mexico
Chapter 10: Eastern Europe Small Interfering RNA (siRNA) Drugs Market Analysis, Insights and Forecast, 2017-2032
10.1 Key Market Trends, Growth Factors and Opportunities
10.2 Impact of Covid-19
10.3 Key Players
10.4 Key Market Trends, Growth Factors and Opportunities
10.4 Historic and Forecasted Market Size By Type
10.4.1 GIVLAARI
10.4.2 Onpattro
10.4.3 OXLUMO
10.4.4 AMVUTTRA
10.4.5 Leqvio
10.5 Historic and Forecasted Market Size By Application
10.5.1 AHP
10.5.2 hATTR
10.5.3 Other
10.6 Historic and Forecast Market Size by Country
10.6.1 Bulgaria
10.6.2 The Czech Republic
10.6.3 Hungary
10.6.4 Poland
10.6.5 Romania
10.6.6 Rest of Eastern Europe
Chapter 11: Western Europe Small Interfering RNA (siRNA) Drugs Market Analysis, Insights and Forecast, 2017-2032
11.1 Key Market Trends, Growth Factors and Opportunities
11.2 Impact of Covid-19
11.3 Key Players
11.4 Key Market Trends, Growth Factors and Opportunities
11.4 Historic and Forecasted Market Size By Type
11.4.1 GIVLAARI
11.4.2 Onpattro
11.4.3 OXLUMO
11.4.4 AMVUTTRA
11.4.5 Leqvio
11.5 Historic and Forecasted Market Size By Application
11.5.1 AHP
11.5.2 hATTR
11.5.3 Other
11.6 Historic and Forecast Market Size by Country
11.6.1 Germany
11.6.2 UK
11.6.3 France
11.6.4 Netherlands
11.6.5 Italy
11.6.6 Russia
11.6.7 Spain
11.6.8 Rest of Western Europe
Chapter 12: Asia Pacific Small Interfering RNA (siRNA) Drugs Market Analysis, Insights and Forecast, 2017-2032
12.1 Key Market Trends, Growth Factors and Opportunities
12.2 Impact of Covid-19
12.3 Key Players
12.4 Key Market Trends, Growth Factors and Opportunities
12.4 Historic and Forecasted Market Size By Type
12.4.1 GIVLAARI
12.4.2 Onpattro
12.4.3 OXLUMO
12.4.4 AMVUTTRA
12.4.5 Leqvio
12.5 Historic and Forecasted Market Size By Application
12.5.1 AHP
12.5.2 hATTR
12.5.3 Other
12.6 Historic and Forecast Market Size by Country
12.6.1 China
12.6.2 India
12.6.3 Japan
12.6.4 South Korea
12.6.5 Malaysia
12.6.6 Thailand
12.6.7 Vietnam
12.6.8 The Philippines
12.6.9 Australia
12.6.10 New Zealand
12.6.11 Rest of APAC
Chapter 13: Middle East & Africa Small Interfering RNA (siRNA) Drugs Market Analysis, Insights and Forecast, 2017-2032
13.1 Key Market Trends, Growth Factors and Opportunities
13.2 Impact of Covid-19
13.3 Key Players
13.4 Key Market Trends, Growth Factors and Opportunities
13.4 Historic and Forecasted Market Size By Type
13.4.1 GIVLAARI
13.4.2 Onpattro
13.4.3 OXLUMO
13.4.4 AMVUTTRA
13.4.5 Leqvio
13.5 Historic and Forecasted Market Size By Application
13.5.1 AHP
13.5.2 hATTR
13.5.3 Other
13.6 Historic and Forecast Market Size by Country
13.6.1 Turkey
13.6.2 Bahrain
13.6.3 Kuwait
13.6.4 Saudi Arabia
13.6.5 Qatar
13.6.6 UAE
13.6.7 Israel
13.6.8 South Africa
Chapter 14: South America Small Interfering RNA (siRNA) Drugs Market Analysis, Insights and Forecast, 2017-2032
14.1 Key Market Trends, Growth Factors and Opportunities
14.2 Impact of Covid-19
14.3 Key Players
14.4 Key Market Trends, Growth Factors and Opportunities
14.4 Historic and Forecasted Market Size By Type
14.4.1 GIVLAARI
14.4.2 Onpattro
14.4.3 OXLUMO
14.4.4 AMVUTTRA
14.4.5 Leqvio
14.5 Historic and Forecasted Market Size By Application
14.5.1 AHP
14.5.2 hATTR
14.5.3 Other
14.6 Historic and Forecast Market Size by Country
14.6.1 Brazil
14.6.2 Argentina
14.6.3 Rest of SA
Chapter 15 Investment Analysis
Chapter 16 Analyst Viewpoint and Conclusion
Small Interfering RNA (siRNA) Drugs Scope:
|
Report Data
|
Small Interfering RNA (siRNA) Drugs Market
|
|
Small Interfering RNA (siRNA) Drugs Market Size in 2022
|
USD 39970 million
|
|
Small Interfering RNA (siRNA) Drugs CAGR 2023 - 2030
|
4.8%
|
|
Small Interfering RNA (siRNA) Drugs Base Year
|
2022
|
|
Small Interfering RNA (siRNA) Drugs Forecast Data
|
2023 - 2030
|
|
Segments Covered
|
By Type, By Application, And by Regions
|
|
Regional Scope
|
North America, Europe, Asia Pacific, Latin America, and Middle East & Africa
|
|
Key Companies Profiled
|
Alnylam, Novartis, Sylentis, Arrowhead, Silence Therapeutics, Dicerna.
|
|
Key Segments
|
By Type
GIVLAARI
Onpattro
OXLUMO
AMVUTTRA
Leqvio
By Applications
AHP
hATTR
Other
|
